Navigation Links
Data on Xeomin® (incobotulinumtoxinA) in the Treatment of Blepharospasm to be Presented at the 115th Annual Meeting of the American Academy of Ophthalmology
Date:10/25/2011

between 18 and 80 years of age at 34 sites in the U.S. and Canada, from October 2006 to May 2008. Eligible patients (n=109) were randomized in a 2:1 ratio to receive XEOMIN or placebo and were followed up to 20 weeks. The selection of doses, dilution, volume and injection sites for treatment was based on the last two Botox® treatments (+/- 10%) prior to the start of the study. Up to 50 Units per eye was allowed.

At each visit, the severity and frequency of blepharospasm symptoms were assessed by the Jankovic Rating Scale (JRS), and the Blepharospasm Disability Index (BSDI) was used to evaluate the effect of XEOMIN on patients' functional impairment. The BSDI evaluates six specific activity items, including watching TV, shopping, walking, reading, driving a vehicle and doing everyday activities. In addition, JRS scores were determined by daily patient self-assessments.

A significant difference was observed in the primary efficacy variable (change in JRS severity subscore rated by an independent rater six weeks following treatment), favoring XEOMIN by 1.0 point (P<.001). No patients discontinued the study prematurely because of insufficient treatment efficacy or adverse events.

All patients who completed the placebo-controlled trial (n=102) were eligible to enter the OLEX, which involved repeat treatment with XEOMIN (up to five treatment sessions) over a period of up to 48 weeks. Investigators determined dosing (up to 50 Units per eye) and frequency of injections, with at least six weeks between sessions.

About XEOMINIn nature, Clostridium botulinum produces botulinum toxin in association with ancillary accessory proteins. Manufacturers utilize this naturally occurring protein complex to produce therapeutic botulinum toxin products. XEOMIN (incobotulinumtoxinA) is manufactured using a proprietary process that isolates the therapeutic component and removes accessory proteins.

More than 250,000 patients have be
'/>"/>

SOURCE Merz Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. FDA Approves Merz Pharmaceuticals Xeomin® (incobotulinumtoxinA) for the Treatment of Cervical Dystonia and Blepharospasm
2. Xeomin® (incobotulinumtoxinA) - a Botulinum Toxin Free From Accessory Proteins - Now Available in the U.S.
3. Xeomin® (incobotulinumtoxinA) Data To Be Presented At The 71st Annual Assembly Of The American Academy Of Physical Medicine And Rehabilitation
4. Merz Pharmaceuticals Introduces Comprehensive Programs to Provide Patients With Financial Assistance for Xeomin® (incobotulinumtoxinA)
5. Merz Pharmaceuticals Announces New Centers for Medicare and Medicaid Billing Q-Code for Xeomin® (incobotulinumtoxinA)
6. New Data On Xeomin® (IncobotulinumtoxinA) To Be Presented At The 15th International Congress Of Parkinsons Disease And Movement Disorders (MDS)
7. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
8. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
9. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
10. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
11. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... 30, 2015 Vermillion, Inc. (VRML), ... disease, announced today it will report its ... market close on Thursday, August 13, 2015, ... webcast at 4:30pm Eastern.Conference Call and Webcast:  ... Eastern/1:30pm Pacific  Domestic: , 888-430-8691International: ...
(Date:7/30/2015)... 2015 What can be expected ... are going to grow at the fastest rates? ... to 2025, assessing data, trends, opportunities and prospects there. ... tables, charts, and graphs. Discover the most lucrative areas ... new study lets you assess forecasted sales at overall ...
(Date:7/30/2015)... 2015  Cleave Biosciences today announced that the ... the company a key patent providing the protection ... This newly issued patent, "Fused pyrimidines ... 9,062,026, allows for claims on the composition of ... inhibitor of p97, a critical enzyme that controls ...
Breaking Medicine Technology:Ophthalmic Devices Market Forecast 2015-2025 - Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 2Ophthalmic Devices Market Forecast 2015-2025 - Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 3Ophthalmic Devices Market Forecast 2015-2025 - Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 4Ophthalmic Devices Market Forecast 2015-2025 - Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 5Ophthalmic Devices Market Forecast 2015-2025 - Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 6
... 2012 Escalon Medical Corp.,s (Nasdaq Market: ESMC) subsidiary, ... successfully completed the outsourced manufacturing of its HbA1c instruments ... sale. Drew has also identified an outsourcing partner for ... available for sale by the summer of 2012.  Drew ...
... Pharmaceuticals, Inc. (Nasdaq: LXRX ) announced today ... and chief executive officer, will present at the RBC Healthcare ... 10:30 a.m. Eastern Time.  Dr. Sands will provide an overview ... A live webcast of the presentation will be available through ...
Cached Medicine Technology:Escalon Announces That the Restructuring of Its IVD Business is Largely Completed 2Escalon Announces That the Restructuring of Its IVD Business is Largely Completed 3Escalon Announces That the Restructuring of Its IVD Business is Largely Completed 4Lexicon Pharmaceuticals to Present at the RBC Healthcare Conference 2
(Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... New research ... Click here to read more on the Surviving Mesothelioma website. , ... Hospital in Missouri reviewed more than 12,000 cases of mesothelioma occurring between 1990 and ...
(Date:7/30/2015)... ... ... Bird B Gone, the leader in bird control products for commercial, industrial ... birds from the AC units and ventilation systems on hospital roofs. Bird droppings can ... Nile virus. When these droppings dry, the fine powder can be carried into hospitals ...
(Date:7/30/2015)... ... July 30, 2015 , ... Author Dr. Raul Llanos seeks to ... his new self-help book, “ Consciously Healing our Webs of Health, Wellbeing, Success, and ... “If we take responsibility for ourselves, we can create better realities.” His book illustrates ...
(Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... After conducting ... , St. John’s Episcopal Hospital in Far Rockaway, N.Y., has hired Gerard ... , With more than 25 years of healthcare leadership experience, Walsh is an expert ...
(Date:7/30/2015)... ... July 30, 2015 , ... After a three year trial ... implant, more commonly known as the “bionic eye,” researchers have determined the trial to ... tool for patients facing or already affected by complete vision loss as a result ...
Breaking Medicine News(10 mins):Health News:Study Finds Mesothelioma Behaves Differently in Younger People, According to Surviving Mesothelioma 2Health News:Bird B Gone’s New Bird Hazing System Keeps Disease-Carrying Bird Droppings Out of Hospitals 2Health News:New book by Dr. Raul Llanos: ‘The power to change is within’ 2Health News:New book by Dr. Raul Llanos: ‘The power to change is within’ 3Health News:St. John’s Episcopal Hospital Hires New Chief Executive Officer 2Health News:St. John’s Episcopal Hospital Hires New Chief Executive Officer 3Health News:St. John’s Episcopal Hospital Hires New Chief Executive Officer 4Health News:St. John’s Episcopal Hospital Hires New Chief Executive Officer 5Health News:The Vision Enhancing “Bionic Eye” Deemed Safe For Long Term Use After Three Year Clinical Trial 2
... Diagnostics, Holding Promise for Melanoma Patients, NEW ... International Melanoma Congress signals new promise,and hope in treating ... for,those in the advanced stages. Caught early, melanoma is ... melanoma is one of the most incurable,and deadly., ...
... 25 Fire evacuation from the comfort of,your home to ... of a,stadium is difficult for anyone. But it,s harder on ... living. Senior Beth Price was overcome with confusion when ... at 2:00 am on Tuesday morning. "We,didn,t get much notice, ...
... Assist in California Fires Response Effort, TALLAHASSEE, Fla., ... to the California wildfires, the Capital Area Chapter of,the ... the effort. "Whether across the country or around ... is prepared to respond to tragedy and in this,case, ...
... The 2007 Southern California,wildfires have disrupted the lives ... tremendous impact on a person emotionally and physically,including ... have,had to evacuate immediately, leaving behind their homes, ... ever be the same. Aside to,evacuees being affected, ...
... help prevent Alzheimer disease , Alzheimer disease (AD), ... of dementia, is characterized by the formation in the ... indicates that some drugs used to treat high blood ... AD. In a new study, in which they screened ...
... air a way out, experts say , THURSDAY, ... treat emphysema patients shows promise, researchers say. , ... (COPD), is a progressive, irreversible lung disease characterized ... are limited. , The new strategy, called airway ...
Cached Medicine News:Health News:Genes Unlock New Treatments for Deadly Melanoma 2Health News:St. Paul's Senior Homes & Services Welcomes Some of San Diego's Neediest Displaced Seniors 2Health News:St. Paul's Senior Homes & Services Welcomes Some of San Diego's Neediest Displaced Seniors 3Health News:Capital Area Chapter Deploys Volunteers to California 2Health News:California Association of Marriage & Family Therapists Offers Tips on How to Cope With a Traumatic Event 2Health News:JCI table of contents: Oct. 25, 2007 2Health News:JCI table of contents: Oct. 25, 2007 3Health News:JCI table of contents: Oct. 25, 2007 4Health News:JCI table of contents: Oct. 25, 2007 5Health News:JCI table of contents: Oct. 25, 2007 6Health News:JCI table of contents: Oct. 25, 2007 7Health News:JCI table of contents: Oct. 25, 2007 8Health News:JCI table of contents: Oct. 25, 2007 9
... The Elite II features ... proven University of Glasgow,(UG) algorithm. ... criteria to age, the UG,algorithm ... clinically,significant criteria: gender, age, race, ...
... face provides three contrast levels (high, 9.5 % ... 20/100. This test is designed to detect very ... contact lens evaluation or due to refractive surgery. ... the same contrast and acuity levels as the ...
The CSV-1000ETDRS10% test face presents the standard ETDRS test at a contrast level of 10%. This test is widely used in clinical studies for the evaluation of refractive surgery and contact lenses....
The CSV-1000-1.5CPD is a special test face designed specifically for Food and Drug Administration clinical trials., ,At the recommended test distance of 8 feet, the gratings test one spatial frequenc...
Medicine Products: